BELGRADE, March 16 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:
- The severity of clinical signs of disease was significantly reduced
- The pathological changes in the myelin sheath (demyelination) were
not detected
- The reduction of mononuclear cell infiltrates, composed of T cells
and macrophages/microglia was observed in the spinal cord tissue
- The degree of disability was lowered
- The duration of the disease was notably shortened
- The percentage mortality in severe disease was radically reduced
(70%)
- The severity of treatment side effects was low and disappeared after
cessation of drug application
In 2005 IBISS group received a prestige reward - The first place and golden medal of Nikola Tesla at the International Festival of Innovations, Know-how and Creativity. The award can be viewed at the company's corporate web site www.htdsmedical.com
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet http://www.pinksheets.com/ filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.
CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at azconsulting2001@gmail.com. Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment